BioCentury
ARTICLE | Distillery Techniques

Disease models

June 28, 2018 5:46 PM UTC

Patient-derived metastatic neuroendocrine prostate cancer organoids could be used to screen therapies for personalized medicine applications. The organoids are generated by culturing enzyme-dissociated cells from samples of a patient’s liver, lymph node and other metastases in a prostate-specific culture media and matrigel, and recapitulated the histological features, DNA methylation, gene expression profiles, drug sensitivity and/or drug resistance of the patient’s tumor. In organoids generated from two patients with alisertib-sensitive and -resistant tumors, screening of approved drugs and small molecules identified two compounds - poziotinib and a tool compound enhancer of zeste homolog 2 (EZH2) inhibitor - that decreased cell viability compared with no treatment. Next steps include using the organoids to screen additional therapies.

Takeda Pharmaceutical Co. Ltd. has alisertib (MLN8237), a second-generation aurora kinase A (AURKA; Aurora-A) inhibitor, in Phase II testing for various cancers and Phase I testing for solid tumors...

BCIQ Company Profiles

Weill Cornell Medicine